Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,360 Mln
P/E Ratio
--
P/B Ratio
1.85
Industry P/E
--
Debt to Equity
0.03
ROE
-0.37 %
ROCE
-35.9 %
Div. Yield
0 %
Book Value
7.5
EPS
-2.58
CFO
$-663.45 Mln
EBITDA
$-1,159.97 Mln
Net Profit
$-1,116.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
| -18.50 | 12.38 | -29.05 | 6.47 | -11.30 | -6.49 | -- |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
| -4.99 | -22.83 | -37.65 | -46.75 | 380.83 | -15.68 | 31.90 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.80 | 10,593.45 | 21.84 | 23.13 | |
| 304.90 | 8,570.17 | 22.78 | 66.44 | |
| 28.39 | 10,589.59 | -- | -28.77 | |
| 106.68 | 10,559.67 | 32.44 | 14.16 |
Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an... IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Address: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 Read more
Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Denali Therapeutics Inc (DNLI) stood at $ 1,374 Mln as on 31-Dec-24
The share price of Denali Therapeutics Inc (DNLI) is $16.61 (NASDAQ) as of 30-Apr-2025 15:38 EDT. Denali Therapeutics Inc (DNLI) has given a return of -11.3% in the last 3 years.
Denali Therapeutics Inc (DNLI) has a market capitalisation of $ 2,360 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Denali Therapeutics Inc (DNLI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Denali Therapeutics Inc (DNLI) and enter the required number of quantities and click on buy to purchase the shares of Denali Therapeutics Inc (DNLI).
Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Address: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Ryan J. Watts Ph.D.. is Denali Therapeutics Inc (DNLI), and CFO & Sr. VP is Dr. Ryan J. Watts Ph.D..
There is no promoter pledging in Denali Therapeutics Inc (DNLI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Denali Therapeutics Inc. (DNLI) | Ratios |
|---|---|
|
Return on equity(%)
|
-37.4
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Denali Therapeutics Inc (DNLI) was $0 Mln.
$0.11
(
